BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30830270)

  • 1. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
    Kado A; Tsutsumi T; Enooku K; Fujinaga H; Ikeuchi K; Okushin K; Moriya K; Yotsuyanagi H; Koike K
    J Gastroenterol; 2019 Aug; 54(8):730-741. PubMed ID: 30830270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver.
    Rau M; Schilling AK; Meertens J; Hering I; Weiss J; Jurowich C; Kudlich T; Hermanns HM; Bantel H; Beyersdorf N; Geier A
    J Immunol; 2016 Jan; 196(1):97-105. PubMed ID: 26621860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations.
    Ali AA; Fouda A; Abdelaziz ES; Abdelkawy K; Ahmed MH
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e954-e960. PubMed ID: 34907983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.
    Wada N; Takaki A; Ikeda F; Yasunaka T; Onji M; Nouso K; Nakatsuka A; Wada J; Koike K; Miyahara K; Shiraha H; Yamamoto K; Okada H
    Hepatol Int; 2017 Jan; 11(1):115-124. PubMed ID: 27826704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
    du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
    Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
    Loomba R; Quehenberger O; Armando A; Dennis EA
    J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    Int J Clin Exp Med; 2014; 7(11):4191-8. PubMed ID: 25550930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
    Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
    Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.
    Arias-Loste MT; Iruzubieta P; Puente Á; Ramos D; Santa Cruz C; Estébanez Á; Llerena S; Alonso-Martín C; San Segundo D; Álvarez L; López Useros A; Fábrega E; López-Hoyos M; Crespo J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis.
    Liu X; Wang Y; Ming Y; Song Y; Zhang J; Chen X; Zeng M; Mao Y
    PLoS One; 2015; 10(5):e0127352. PubMed ID: 25993652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.
    De A; Duseja A
    J Clin Exp Hepatol; 2020; 10(3):255-262. PubMed ID: 32405182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis.
    Fujii Y; Nouso K; Matsushita H; Kariyama K; Sakurai T; Takahashi Y; Chiba H; Hui SP; Ito Y; Ohta M; Okada H
    J Appl Lab Med; 2020 Nov; 5(6):1206-1215. PubMed ID: 32674154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.